Metabolic characteristics of obese patients with polycystic ovarian syndrome: a meta-analysis

References

• Wu Q, Gao J, Bai D, et al. The prevalence of polycystic ovarian syndrome in Chinese women: a meta-analysis. Ann Palliat Med. 2021;10(1):1–10. doi: 10.21037/apm-20-1893.
   PubMed Web of Science ®Google Scholar
• Lim SS, Kakoly NS, Tan JWJ, et al. Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Obes Rev. 2019;20(2):339–352. doi: 10.1111/obr.12762.
   PubMed Web of Science ®Google Scholar
• Li A, Zhang L, Jiang J, et al. Follicular hyperandrogenism and insulin resistance in polycystic ovary syndrome patients with normal circulating testosterone levels. J Biomed Res. 2017;208–214.
   PubMed Web of Science ®Google Scholar
• Ma X, Hayes E, Prizant H, et al. Leptin-induced CART (cocaine- and amphetamine-regulated transcript) is a novel intraovarian mediator of obesity-related infertility in females. Endocrinology. 2016;157(3):1248–1257. doi: 10.1210/en.2015-1750.
   PubMed Web of Science ®Google Scholar
• Cena H, Chiovato L, Nappi RE. Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists. J Clin Endocrinol Metab. 2020;105(8):e2695–e2709. doi: 10.1210/clinem/dgaa285.
   PubMed Web of Science ®Google Scholar
• Jena D, Choudhury AK, Mangaraj S, et al. Study of visceral and subcutaneous abdominal fat thickness and its correlation with cardiometabolic risk factors and hormonal parameters in polycystic ovary syndrome. Indian J Endocrinol Metab. 2018;22(3):321–327. doi: 10.4103/ijem.IJEM_646_17.
   PubMedGoogle Scholar
• Lazurova I, Lazurova Z, Figurova J, et al. Relationship between steroid hormones and metabolic profile in women with polycystic ovary syndrome. Physiol Res. 2019;68(3):457–465. doi: 10.33549/physiolres.934062.
   PubMed Web of Science ®Google Scholar
• Faloia E, Canibus P, Gatti C, et al. Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome. J Endocrinol Invest. 2004;27(5):424–429. doi: 10.1007/BF03345285.
   PubMed Web of Science ®Google Scholar
• Siddiqui IA, Tamimi W, Tamim H, et al. A study on clinical and sonographic features in obese and nonobese patients with polycystic ovary syndrome. Arch Gynecol Obstet. 2010;281(3):467–471. doi: 10.1007/s00404-009-1124-y.
   PubMed Web of Science ®Google Scholar
• Rashad NM, Al-Sayed RM, Yousef MS, et al. Kisspeptin and body weight homeostasis in relation to phenotypic features of polycystic ovary syndrome; metabolic regulation of reproduction. Diabetes Metab Syndr. 2019;13(3):2086–2092. doi: 10.1016/j.dsx.2019.04.017.
   PubMed Web of Science ®Google Scholar
• Kurek Eken M, Sahin Ersoy G, Yayla Abide C, et al. Association between circulating neuregulin 4 levels and metabolic, aterogenic, and AMH profile of polycystic ovary syndrome. J Obstet Gynaecol. 2019;39(7):975–980. doi: 10.1080/01443615.2019.1581754.
   PubMedGoogle Scholar
• Chantrapanichkul P, Indhavivadhana S, Wongwananuruk T, et al. Prevalence of type 2 diabetes mellitus compared between lean and overweight/obese patients with polycystic ovarian syndrome: a 5-year follow-up study. Arch Gynecol Obstet. 2020;301(3):809–816. doi: 10.1007/s00404-019-05423-2.
   PubMed Web of Science ®Google Scholar
• Saxena P, Prakash A, Nigam A, et al. Polycystic ovary syndrome: is obesity a sine qua non? A clinical, hormonal, and metabolic assessment in relation to body mass index. Indian J Endocrinol Metab. 2012;16(6):996–999. doi: 10.4103/2230-8210.103011.
   PubMedGoogle Scholar
• Baldani DP, Skrgatic L, Goldstajn MS, et al. Clinical, hormonal and metabolic characteristics of polycystic ovary syndrome among obese and nonobese women in the Croatian population. Coll Antropol. 2013;37(2):465–470.
   PubMedGoogle Scholar
• Gul OO, Cander S, Gul B, et al. Evaluation of insulin resistance and plasma levels for visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome. Eur Cytokine Netw. 2015;26(4):73–78. doi: 10.1684/ecn.2015.0370.
   PubMed Web of Science ®Google Scholar
• Abdul-Maksoud RS, Zidan HE, Saleh HS, et al. Visfatin and SREBP-1c mRNA expressions and serum levels among Egyptian women with polycystic ovary syndrome. Genet Test Mol Biomarkers. 2020;24(7):409–419. doi: 10.1089/gtmb.2019.0192.
   PubMed Web of Science ®Google Scholar
• Kiddy DS, Sharp PS, White DM, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol (Oxf). 1990;32(2):213–220. doi: 10.1111/j.1365-2265.1990.tb00857.x.
   PubMed Web of Science ®Google Scholar
• Silfen ME, Denburg MR, Manibo AM, et al. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab. 2003;88(10):4682–4688. doi: 10.1210/jc.2003-030617.
   PubMed Web of Science ®Google Scholar
• Neubronner SA, Indran IR, Chan YH, et al. Effect of body mass index (BMI) on phenotypic features of polycystic ovary syndrome (PCOS) in Singapore women: a prospective cross-sectional study. BMC Womens Health. 2021;21(1):135.
   PubMed Web of Science ®Google Scholar
• Moradi S, Mollabashi M, Kerman SR. Relation between C-reactive protein and body mass index in patients with polycystic ovarian syndrome. Gynecol Endocrinol. 2011;27(7):480–485. doi: 10.3109/09513590.2010.501876.
   PubMed Web of Science ®Google Scholar
• Eldar-Geva T, Spitz IM, Groome NP, et al. Follistatin and activin a serum concentrations in obese and non-obese patients with polycystic ovary syndrome. Hum Reprod. 2001;16(12):2552–2556. doi: 10.1093/humrep/16.12.2552.
   PubMed Web of Science ®Google Scholar
• Stein I, Leventhal M. Amenorrhea associated with bilateral polycystic ovaries. American Journal of Obstetrics and Gynecology. 1935;29(2):181–191. (doi: 10.1016/S0002-9378(15)30642-6.
   Google Scholar
• Rotterdam EA-SPCWG. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25.
   Web of Science ®Google Scholar
• Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602–1618. doi: 10.1093/humrep/dey256.
   PubMed Web of Science ®Google Scholar
• Sirotkin AV, Fabian D, Babeľová Kubandová J, et al. Body fat affects mouse reproduction, ovarian hormone release, and response to follicular stimulating hormone. Reprod Biol. 2018;18(1):5–11. doi: 10.1016/j.repbio.2017.12.002.
   PubMed Web of Science ®Google Scholar
• Delitala AP, Capobianco G, Delitala G, et al. Polycystic ovary syndrome, adipose tissue and metabolic syndrome. Arch Gynecol Obstet. 2017;296(3):405–419. doi: 10.1007/s00404-017-4429-2.
   PubMed Web of Science ®Google Scholar
• Shorakae S, Abell SK, Hiam DS, et al. High-molecular-weight adiponectin is inversely associated with sympathetic activity in polycystic ovary syndrome. Fertil Steril. 2018;109(3):532–539. doi: 10.1016/j.fertnstert.2017.11.020.
   PubMed Web of Science ®Google Scholar
• Milutinovic DV, Nikolic M, Velickovic N, et al. Enhanced inflammation without impairment of insulin signaling in the visceral adipose tissue of 5alpha-Dihydrotestosterone-Induced animal model of polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2017;125(8):522–529.
   PubMed Web of Science ®Google Scholar
• Corbould A. Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women. J Endocrinol. 2007;192(3):585–594. doi: 10.1677/joe.1.07070.
   PubMed Web of Science ®Google Scholar
• Corton M, Botella-Carretero JI, Benguria A, et al. Differential gene expression profile in omental adipose tissue in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92(1):328–337. doi: 10.1210/jc.2006-1665.
   PubMed Web of Science ®Google Scholar
• Li L, Feng Q, Ye M, et al. Metabolic effect of obesity on polycystic ovary syndrome in adolescents: a meta-analysis. J Obstet Gynaecol. 2017;37(8):1036–1047. doi: 10.1080/01443615.2017.1318840.
   PubMedGoogle Scholar
• Barber TM, Kyrou I, Randeva HS, et al. Mechanisms of insulin resistance at the crossroad of obesity with associated metabolic abnormalities and cognitive dysfunction. Int J Mol Sci. 2021;22(2):546. doi: 10.3390/ijms22020546.
   PubMed Web of Science ®Google Scholar
• Zeng X, Xie YJ, Liu YT, et al. Polycystic ovarian syndrome: correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2020;502:214–221. doi: 10.1016/j.cca.2019.11.003.
   PubMed Web of Science ®Google Scholar
• Lim SS, Norman RJ, Davies MJ, et al. The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obes Rev. 2013;14(2):95–109. doi: 10.1111/j.1467-789X.2012.01053.x.
   PubMed Web of Science ®Google Scholar
• Legro RS. Obesity and PCOS: implications for diagnosis and treatment. Semin Reprod Med. 2012;30(6):496–506. doi: 10.1055/s-0032-1328878.
   PubMed Web of Science ®Google Scholar
• Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): long-term metabolic consequences. Metabolism. 2018;86:33–43. doi: 10.1016/j.metabol.2017.09.016.
   PubMed Web of Science ®Google Scholar